MA34008B1 - COMPOUNDS AS ANTAGONISTS OF BRADYKININ B1 - Google Patents
COMPOUNDS AS ANTAGONISTS OF BRADYKININ B1Info
- Publication number
- MA34008B1 MA34008B1 MA35153A MA35153A MA34008B1 MA 34008 B1 MA34008 B1 MA 34008B1 MA 35153 A MA35153 A MA 35153A MA 35153 A MA35153 A MA 35153A MA 34008 B1 MA34008 B1 MA 34008B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- bradykinin
- antagonists
- preparation
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
- C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne les composés de formule générale (i) dans laquelle n, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11 et x sont tels que définis ci-dessous, leurs énantiomères, leurs diastéréomères, leurs mélanges et leurs sels, en particulier leurs sels physiologiquement acceptables contenant des bases ou des acides organiques ou inorganiques, lesquels présentent des propriétés précieuses, leur préparation, les médicaments contenant les composés pharmacologiquement actifs, leur préparation et leur utilisation.The present invention relates to the compounds of general formula (i) in which n, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11 and x are as defined below, their enantiomers, their diastereomers, their mixtures and their salts, in particular their physiologically acceptable salts containing organic or inorganic bases or acids, which exhibit valuable properties, their preparation, drugs containing pharmacologically active compounds, their preparation and their use.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/052232 WO2010097372A1 (en) | 2009-02-26 | 2010-02-23 | Compounds as bradykinin b1 antagonists |
| PCT/EP2011/052512 WO2011104203A1 (en) | 2010-02-23 | 2011-02-21 | Compounds as bradykinin b1 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34008B1 true MA34008B1 (en) | 2013-02-01 |
Family
ID=43981434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35153A MA34008B1 (en) | 2010-02-23 | 2011-02-21 | COMPOUNDS AS ANTAGONISTS OF BRADYKININ B1 |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP2539323B3 (en) |
| JP (1) | JP5603955B2 (en) |
| KR (1) | KR101843341B1 (en) |
| CN (2) | CN102781916B (en) |
| AP (1) | AP3218A (en) |
| AR (1) | AR080249A1 (en) |
| AU (1) | AU2011219885C1 (en) |
| CA (1) | CA2790952C (en) |
| CY (1) | CY1116182T1 (en) |
| DK (1) | DK2539323T6 (en) |
| ES (1) | ES2531663T7 (en) |
| HK (1) | HK1175171A1 (en) |
| IL (1) | IL220680A (en) |
| MA (1) | MA34008B1 (en) |
| MX (1) | MX2012009224A (en) |
| NZ (1) | NZ601194A (en) |
| PE (1) | PE20121805A1 (en) |
| PL (1) | PL2539323T6 (en) |
| PT (1) | PT2539323E (en) |
| SG (1) | SG183336A1 (en) |
| SI (1) | SI2539323T1 (en) |
| TW (1) | TWI499589B (en) |
| WO (1) | WO2011104203A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007034620A1 (en) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New B1 antagonists |
| JP5238812B2 (en) | 2007-08-29 | 2013-07-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel bradykinin B1 antagonist |
| CN102781916B (en) | 2010-02-23 | 2014-06-25 | 贝林格尔.英格海姆国际有限公司 | Compounds as bradykinin B1 antagonists |
| US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
| US8901127B2 (en) | 2010-08-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Pyridazin derivatives as antagonists of the bradykinin B1 receptor |
| JP7376582B2 (en) * | 2018-10-22 | 2023-11-08 | イーオーイー オレオ ゲーエムベーハー | Additive for powder materials for compression into compacts |
| WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
| WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038377A1 (en) * | 2002-02-08 | 2005-01-12 | Merck & Co Inc | DERIVATIVES OF N-BIFENIL-AMINOCICLOALCANCARBOXAMIDA (WITH REPLACEMENT WITH METHYL) |
| RU2005108667A (en) * | 2002-08-29 | 2005-08-27 | Мерк энд Ко., Инк. (US) | N-BIARILMETHYLAMINOCYCLOCALACANBOXAMIDE DERIVATIVES |
| WO2005016886A1 (en) * | 2003-08-07 | 2005-02-24 | Merck & Co., Inc. | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides |
| WO2005085198A2 (en) * | 2004-03-02 | 2005-09-15 | Merck & Co., Inc. | Amino cyclopropane carboxamide derivatives as bradykinin antagonists |
| MX2007013766A (en) | 2005-05-11 | 2008-01-28 | Nycomed Gmbh | Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative. |
| HUP0600809A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| MY153941A (en) * | 2009-02-26 | 2015-04-15 | Boehringer Ingelheim Int | Compounds as bradykinin b1 antagonists |
| CN102781916B (en) | 2010-02-23 | 2014-06-25 | 贝林格尔.英格海姆国际有限公司 | Compounds as bradykinin B1 antagonists |
-
2011
- 2011-02-21 CN CN201180009563.1A patent/CN102781916B/en not_active Expired - Fee Related
- 2011-02-21 MX MX2012009224A patent/MX2012009224A/en active IP Right Grant
- 2011-02-21 ES ES11705858.6T patent/ES2531663T7/en active Active
- 2011-02-21 PL PL11705858T patent/PL2539323T6/en unknown
- 2011-02-21 CN CN201410206948.2A patent/CN103980258B/en not_active Expired - Fee Related
- 2011-02-21 EP EP11705858.6A patent/EP2539323B3/en active Active
- 2011-02-21 MA MA35153A patent/MA34008B1/en unknown
- 2011-02-21 CA CA2790952A patent/CA2790952C/en not_active Expired - Fee Related
- 2011-02-21 PT PT117058586T patent/PT2539323E/en unknown
- 2011-02-21 DK DK11705858.6T patent/DK2539323T6/en active
- 2011-02-21 AU AU2011219885A patent/AU2011219885C1/en not_active Ceased
- 2011-02-21 AP AP2012006330A patent/AP3218A/en active
- 2011-02-21 SI SI201130402T patent/SI2539323T1/en unknown
- 2011-02-21 PE PE2012001250A patent/PE20121805A1/en not_active Application Discontinuation
- 2011-02-21 SG SG2012060620A patent/SG183336A1/en unknown
- 2011-02-21 KR KR1020127021929A patent/KR101843341B1/en active IP Right Grant
- 2011-02-21 NZ NZ601194A patent/NZ601194A/en not_active IP Right Cessation
- 2011-02-21 JP JP2012553341A patent/JP5603955B2/en active Active
- 2011-02-21 WO PCT/EP2011/052512 patent/WO2011104203A1/en active Application Filing
- 2011-02-22 AR ARP110100542A patent/AR080249A1/en not_active Application Discontinuation
- 2011-02-22 TW TW100105851A patent/TWI499589B/en active
-
2012
- 2012-06-28 IL IL220680A patent/IL220680A/en not_active IP Right Cessation
-
2013
- 2013-02-26 HK HK13102358.7A patent/HK1175171A1/en not_active IP Right Cessation
-
2015
- 2015-03-02 CY CY20151100211T patent/CY1116182T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34008B1 (en) | COMPOUNDS AS ANTAGONISTS OF BRADYKININ B1 | |
| MA33238B1 (en) | COMPOUNDS AS ANTAGONISTS OF BRADYKININ B1 | |
| MA42231B1 (en) | New hydroxy acid derivatives, process for their preparation, and pharmaceutical compositions containing them | |
| MA37400B1 (en) | Heterocyclyl compounds as mek inhibitors | |
| MA42230A (en) | BICYCLIC DERIVATIVES, THEIR PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| TN2009000471A1 (en) | AMINO-HETEROCYCLIC COMPOUNDS | |
| MA45223A (en) | NEW PIPERIDINYL DERIVATIVES SUBSITATED BY (HETERO) ARYL, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| MA45222B1 (en) | Novel piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | |
| MA43639B1 (en) | New ammonium derivatives, process for their preparation and pharmaceutical compositions containing them | |
| MA34340B1 (en) | HETEROARYL COMPOUNDS CONTAINING NITROGEN | |
| MA38138A1 (en) | New derivatives of quinolone | |
| TN2009000450A1 (en) | PYRIDINE DERIVATIVES | |
| EA200970510A1 (en) | HETEROMONOCYCLIC COMPOUND AND ITS APPLICATION | |
| MA35576B1 (en) | New compounds | |
| MA35348B1 (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as inhibitors of btk | |
| HRP20040686B1 (en) | Novel heterocyclic compounds which are active as inhibitors of beta-lactamases | |
| MA33239B1 (en) | 3h Imidazo - [4,5-c] pyridine-6-carboxamide as an anti-inflammatory | |
| MA32509B1 (en) | ORGANIC COMPOUNDS | |
| MA27775A1 (en) | ORGANIC COMPOUNDS | |
| TNSN08139A1 (en) | THERAPEUTIC COMPOUNDS | |
| MA30487B1 (en) | NEW HETEROCYCLIC COMPOUNDS | |
| PE20090363A1 (en) | MODULATORS OF THE GAMMA SECRETASE | |
| MA49127B1 (en) | N-substituted indole derivatives | |
| TN2010000173A1 (en) | CGRP ANTAGONISTS | |
| MA38854B1 (en) | Amide derivatives used as lysophosphatidic acid receptor antagonists |